What could your deciding factor be?

Find a treatment specifically created for von Willebrand disease (VWD) bleeding episodes1

As an adult living with VWD, you may share a bleeding disorder with others, but you also may have your own Deciding Factor—something that drives you to ask your healthcare provider about finding a treatment that's right for you.

Real VWD patients using VONVENDI as a treament to help reduce bleeding.
The only VWD factor treatment that's manufactured without human blood or plasma.

The only VWD factor treatment that's manufactured without human blood or plasma.2,3

VONVENDI® can be used with or without recombinant FVIII as directed.

Can be used with or without recombinant FVIII as directed.1

Created specifically to
treat VWD

VONVENDI® is used to treat bleeds in adults with von Willebrand disease (VWD), an inherited bleeding disorder that makes it difficult to form blood clots.1 VONVENDI is the first and only recombinant treatment for VWD, meaning it's made without using human blood.2,3 Recombinant products have virtually no risk of being exposed to disease that can be spread through contamination by infected human blood.2

Learn about VONVENDI

Living with VWD

VWD can change your life, and no one knows that experience better than the people who face it every day.

Learn about VWD
Real VWD patient Leslie standing on a rock with her outdoor outfit shares her deciding factor: Loving my outdoor lifestyle.
Nicole, Real VWD patient smiling.
Try for free

You may be eligible to try VONVENDI for free with
our FREEDOM OF CHOICE program.

Learn more
Patient discussing his VWD condition with a specialized healthcare provider at Hemophilia treatment center. Find a local a treatment center.
Discussion Guide

A guide to help you talk to your healthcare provider about finding a treatment that's right for you.

Download now

References

  1. VONVENDI Prescribing Information
  2. Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825-830.
  3. Baxalta receives FDA Approval for VONVENDI, the first and only recombinant treatment for adults affected by von Willebrand disease. Business Wire. December 8, 2015. Accessed July 9, 2020. https://www.businesswire.com/news/home/20151208006689/en/Baxalta-Receives-FDA-Approval-VONVENDIRecombinant-Treatment
divider line between content and footer